Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Liwei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0031-4363; OpenAlex author ID A5100406712. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. Upregulation of Lactobacillus spp. in gut microbiota as a novel mechanism for environmental eustress-induced anti-pancreatic cancer effects. Co-author DOI 10.1080/19490976.2025.2470372↗
  2. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Last author DOI 10.1016/j.jncc.2022.08.006↗
  3. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Last author DOI 10.1038/s41421-021-00271-4↗
  4. Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china. Last author DOI 10.1080/14737167.2020.1812386↗
  5. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-021-08375-6↗
  6. A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer. Last author DOI 10.21037/tcr-20-3478↗
  7. The prognostic and predictive value of the albumin-bilirubin score in advanced pancreatic cancer. Last author DOI 10.1097/md.0000000000020654↗
  8. A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/jca.23984↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 7 shared papers, 2018–2025 · strength 0.92
  2. Feng Jiao · 5 shared papers, 2018–2022 · strength 0.51
  3. Yiyi Liang · 3 shared papers, 2021–2025 · strength 0.44
  4. Tiebo Mao · 3 shared papers, 2021 · strength 0.34
  5. Haiyan Yang · 2 shared papers, 2021 · strength 0.24
  6. Jiayu Yao · 2 shared papers, 2021 · strength 0.23
  7. Jiong Hu · 2 shared papers, 2021 · strength 0.21
  8. Yu Wang · 2 shared papers, 2021 · strength 0.21
  9. Yu Gan · 1 shared paper, 2025 · strength 0.21
  10. Hong Tu · 1 shared paper, 2025 · strength 0.21
  11. Jin Li · 1 shared paper, 2025 · strength 0.21
  12. Hui Cong · 1 shared paper, 2025 · strength 0.21
  13. Yongwei Sun · 2 shared papers, 2021–2022 · strength 0.19
  14. Deliang Fu · 2 shared papers, 2021–2022 · strength 0.19
  15. Tiening Zhang · 1 shared paper, 2020 · strength 0.19
  16. Ting Han · 1 shared paper, 2021 · strength 0.11
  17. Xiaofei Zhang · 1 shared paper, 2021 · strength 0.10
  18. Qing Xia · 1 shared paper, 2021 · strength 0.10
  19. Jing Xue · 1 shared paper, 2021 · strength 0.10
  20. Zheng Wang · 1 shared paper, 2022 · strength 0.09
  21. Zhiwei Li · 1 shared paper, 2022 · strength 0.09
  22. Tao Zhang · 1 shared paper, 2022 · strength 0.09
  23. Qingyong Ma · 1 shared paper, 2022 · strength 0.09
  24. Chunyi Hao · 1 shared paper, 2022 · strength 0.09
  25. Gang Ren · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.